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Effect of UCHL1 on CHT expression was examined in a cholinergic neuronal cell line, SN56.
TUBE pull-down assay indicated poly-ubiquitination of CHT.
CHT immunoprecipitation revealed physical interaction between UCHL1 and CHT.
Reduction of UCHL1 by siRNA gene knockdown signiﬁcantly increased poly-ubiquitinated CHT and decreased native CHT protein level.
UCHL1 was present in cytosol and reduction of UCHL1 reduced the cytosolic CHT but not the plasma membrane CHT.
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a b s t r a c t
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme, which is highly
expressed in neuronal cells. Previous studies have indicated that UCHL1 is involved in cognitive function,
neurodegenerative diseases, and neuromuscular junction development. Acetylcholine (Ach) is a critical
neurotransmitter in these functions. Yet, the effect of UCHL1 on the cholinergic system has not been
reported. In this study, using a cholinergic neuronal cell line, SN56, as an in vitro model, we detected
the physical interaction of UCHL1 and high afﬁnity choline transporter (CHT), which is a key protein
regulating Ach re-synthesis. Reduction of UCHL1 by siRNA gene knockdown signiﬁcantly increased poly-cetylcholine
biquitination
N56 cells
ubiquitinated CHT and decreased native CHT protein level, but did not affect CHT mRNA expression.
Biotinylation assay showed that UCHL1 is localized only in the cytosol of the cells and that the gene
knockdown of UCHL1 signiﬁcantly reduced cytosolic CHT but had no signiﬁcant effect onmembrane CHT
level. These data provide novel and potentially important evidence that UCHL1 may play a role in the
regulation of cholinergic function by affecting CHT ubiquitination and degradation.
© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.. Introduction
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) was origi-
ally found as a “brain speciﬁc protein”, named “PGP9.5” [14], and
ater functionally conﬁrmed as a ubiquitin hydrolase [29]. UCHL1
s highly expressed in both central and peripheral nervous systems
nd has been widely used as a neuronal marker [8]. UCHL1 is a
ember of UCH deubiquitinating enzymes (DUBs) family [20,23].
s a DUB, UCHL1 was reported to cleave small but not large sub-
trates from the C-terminal of ubiquitin [16], and to bind and
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304-3940 © 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under Cstabilize mono-ubiquitin [21]. In addition, there is evidence that
overexpressed and dimerized UCHL1 exhibits ubiquitin E3 ligase
activity [17].
Evidence suggests that UCHL1 is essential for the proper devel-
opment and function of nervous systems. Mice with a spontaneous
deletion of exons 7 and 8 in the UCHL1 gene, also known as gracile
axonal dystrophy (GAD)mice, lack a functional UCHL1 and develop
an abnormal shufﬂing movement followed by hind-limb paraly-
sis and early death [32]. A recent study further shows that UCHL1
gene knockout mice exhibit impaired structure and function of
neuromuscular junction [5]. Additionally, altered UCHL1 has been
linked to neurodegenerative diseases. In the brain of patients with
Parkinson’s andAlzheimer’sdisease (AD),UCHL1protein levelwere
reduced [6]. In an animal experiment, the administration of UCHL1
protein fusedwithHIV transactivator (TAT) protein provided a pro-
tective effect against beta-amyloid-induced decreases in synaptic
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As an important neurotransmitter, acetylcholine (Ach) is par-
icularly important in cognitive activities [27] and neuromuscular
unction function [30]. Yet, whether UCHL1 has any effect on the
ch system in physiological and pathophysiological conditions has
ot been reported. High afﬁnity choline transporter (CHT) is criti-
al for Ach re-synthesis [26] and is essential formaintaining central
nd peripheral cholinergic function [1,9]. CHT undergoes dynamic
rafﬁcking between plasmamembrane and cytosol [3,24,25]. Given
he role of UCHL1 in cognitive function, neurodegenerative dis-
ases, and neuromuscular junction, it would be conceivable to
peculate the potential link between the UCHL1 and CHT. In this
hort communication, we report novel evidence indicating the
nteraction of UCHL1 with CHT in a cholinergic cell line, SN56.
. Methods
.1. Cell culture and protein extraction
SN56 cholinergic neuronal cells were kindly provided by Dr.
. K. Blusztajn of Boston University School of Medicine. This cell
ine expresses major cholinergic components including choline
cetyltransferase (ChAT), choline transporter (CHT), and vesicular
cetylcholine transporter (VAChT) [2,12,22]. Cells were cultured in
MEMsupplementedwith l-glutamine, sodiumpyruvate, 10% fetal
ovine serum (FBS) and 1% penicillin and streptomycin. At the end
f the treatments, cellswerewashedwithpre-chilled PBS, collected
y scrapping, and lysed using RIPA buffer (10mM sodium phos-
hate, pH 7.6, 80mMNaCl, 0.5% sodiumdeoxycholate, 0.2% sodium
uoride, and 1% NP-40) with freshly added protease inhibitors
ocktail (Pierce Inc. Rockford, IL). After centrifugation at 10,000× g
or 10min at 4 ◦C, cell lysate supernatant was collected. Protein
oncentrationwas assayed using a BCA kit (Pierce) and normalized.
.2. TUBE assay and CHT immunoprecipitation
Tandem ubiquitin binding entities (TUBEs, LifeSensors, Inc.
alvern, PA) are novel, sensitive approaches of afﬁnity isolation
f ubiquitinated proteins [13]. Cell lysate samples with the nor-
alized protein concentration were loaded into a tube containing
re-equilibrated TUBE1 beads or control beads and incubated at
◦C overnight with rotation. The beads were then collected by
entrifugation at 3000× g for 1min. The supernatant sample was
emoved from the beads and saved as the “unbound” sample. The
eads were washed twice with 1ml TBST each, and re-suspended
ith RIPA buffer containing BME loading butter. The bound pro-
eins were eluted by boiling for 10min. The “pull-down” samples,
long with “total input” and “unbound” samples were subjected to
tandard immunoblotting.
For immunoprecipitation (IP), the cell lysate sample with nor-
alized protein concentration was loaded into a 1.7ml tube and
ncubated with a rabbit-anti CHT antibody (a custom antibody [10]
roducedbyGenemedSynthesis, SanAntonio, TX), or equal amount
f rabbit IgG as control, at 4 ◦C for 1h. The mixture was transferred
nto a tube containing pre-washed protein G-agarose beads and
ncubated overnight at 4 ◦C with rotation. Beads were collected
y centrifugation and washed twice with PBS. The bound proteins
ere eluted into RIPA buffer containing BME loading buffer by boil-
ng for 10min. Pull-downsampleswere subject to immunoblotting.
.3. UCHL1 gene knockdown
The siRNA reagentswere purchased from IntegrationDNATech-
ologies, Inc. (Coralville, Iowa). Two microliters of 20M stock
iRNA targeting UCHL1 or control siRNA were diluted in 100l of
pt-MEM medium (Life Technologies, Co., Grand Island, NY), fur-
hermixedwith100l ofOpt-MEMcontaining4l of Lipofectaminetters 564 (2014) 115–119
RNAiMax (Life Technologies, Co.), and incubated at room tempera-
ture for 5min. The siRNA mixture was then added into SN56 cells
in a culture dish with 1.8ml medium. After 24–48h of treatment,
cells were lysed for immunoblotting, subject to biotinylation, or for
RNA isolation.
2.4. Semi-quantitative RT-PCR
After 48h of treatment with siRNA targeting UCHL1 or control
siRNA, cells were washed with PBS and subject to RNA isolation
using TRIzol reagent (Life Technologies Co.) and RNA clean-up kit
(ZYMO Research, Orange, CA). RT-PCR was carried out as described
in our previous publication [15]. The primers were purchased
from Integration DNA Technologies, Inc. For CHT (gene accession
numberNM 053521.1), the forward primerwas ATTGATTGATCGC-
CTCGCCC and reverse primer AGCCCAAGCTAGACCACAAC; for beta
actin (gene accession number NM 031144.3), forward primer
ACCCGCGAGTACAACCTTCT; and reverse primer ATGGCTACGTA-
CATGGCTGG.
2.5. Plasma membrane protein biotinylation
Cells were washed with pre-chilled PBS containing 1mM CaCl2
and 1mM MgCl2, and incubated with 1.5mg/ml sulfo–NHS–biotin
(Pierce, Inc.) for 1h at room temperature. Excessive biotinylating
reagents were removed by incubating with 100mM pre-chilled
glycine in PBS, followed by three washes with cold PBS/Ca2+-Mg2+.
Cells were then lysed in RIPA buffer containing protease inhibitor
cocktail (Pierce, Inc). Following centrifugation at 5000× g for 5min
at 4 ◦C, the supernatants were incubated with prewashed Neutra-
vidin beads (Pierce, Inc) with rotation at room temperature for
1h. The beads were pulled down by centrifugation at 3000× g for
1min. The supernatantswere saved as cytosolic samples. The beads
werewashedwithPBS twice and theboundplasmamembranepro-
teins were eluted into RIPA buffer containing BME loading buffer
by boiling for 10min. The samples were subject to immunoblot-
ting.
2.6. Western blot
Cell lysate samples from above experiments were mixed with
loading buffer, boiled, and subjected to standard SDS-PAGE and
transfer procedures as described previously [15]. Immunoblot-
ting was conducted using primary antibodies against ubiquitin
(Sigma–Aldrich, St. Louis, MO), CHT (a custom antibody [10] pro-
duced by Genemed Synthesis, San Antonio, TX), UCHL1, actin or
GAPDH (Santa Cruz Inc. CA) and appropriate secondary antibodies
conjugated with ﬂuorescent dyes. The bands were detected using
an Odyssey scanner (LI-COR Inc, Lincoln, NE) and quantiﬁed using
NIH ImageJ software.
2.7. Data analysis
The quantiﬁcation of immunoblotting bands were ﬁrst nor-
malized as relative densities against loading control (actin or
GAPDH) bands and then calculated as the ratio of treatment
group versus control group. All quantiﬁed data were expressed
as mean± standard deviation (SD). Data were analyzed and com-
pared using single factor ANOVA. The statistical signiﬁcances
between the compared groups were determined by p value equal
or less than 0.05. Sample sizes (n) were indicated in individual
ﬁgures.
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Fig. 1. TUBE pull-down and CHT IP pull-down. (A) TUBE pull-down. Western blot for ubiquitin (top) shows the poly-ubiquitinated proteins in the total input sample (total
lane), enriched poly-ubiquitinated proteins in the TUBE1 pull-down sample (TUBE1 lane), and consequently reduced poly-ubiquitination signal in the supernatant sample

















(TUBE1 lane) and consequently reduced in the TUBE1 unbound sample. (B) CHT IP
top, lane 3, indicated by an arrow) and the ∼25kDa UCHL1 band (bottom, lane 3, in
eads (lane 2, top and bottom).
. Results
.1. TUBE pull-down and CHT IP
As shown in Fig. 1 panel A, poly-ubiquitinated proteins at the
ighmolecular rangeweremarkedly enriched in the TUBE1pulled-
own fraction sample (Fig. 1A, top panel, lane 4) versus the sample
ulled down by control beads (lane 2), indicating the efﬁcacy of
biquitin afﬁnity pull-down by TUBE. Immunoblotting for CHT
etectedbands at thehighmolecular range in the TUBE1pull-down
ample but not in the control beads pull-down sample (Fig. 1A,
ig. 2. Altered poly-ubiquitinated and native CHT by UCHL1 knockdown. (A) Representa
n poly-ubiquitinated CHT, native CHT (∼55kDa band), or UCHL1 proteins from SN56 cell
ars). The data were calculated as relative densities of the bands of interest against the b
s the control group. (All groups n=14). (B) Representative semi-quantitative RT-PCR (top
he control siRNA cells (black bar) and UCHL1 siRNA cells (gray bar). The data were calcul
All groups n=3).g the respective primary antibodies, western blot detected the ∼55kDa CHT band
d by an arrow). These bands were absent in the sample pulled down by the control
bottom panel, lane 4 vs 2), indicating that poly-ubiquitinated CHT
proteins were pulled down by TUBE. According to the manufac-
turer’s instruction, TUBE1 has higher afﬁnity for K63 linkages over
other ubiquitin lysine linkages such as K48, whereas TUBE2 has
equal afﬁnity for all types of linkages. Accordingly, we also con-
ducted a pull-down assay using TUBE2 and received similar results
as TUBE1 (data not shown). The type of ubiquitin linkage attached
to CHT remains to be further veriﬁed using linkage-speciﬁc anti-
bodies.
For CHT IP results as shown in Fig. 1 panel B, immunoblotting
detected CHT (Fig. 1B, top panel) as well as UCHL1 (Fig. 1B, bottom
tive western blots (top) and quantitative data (bottom, bar graphs) show changes
s that were treated with control siRNA (black bars) or siRNA targeting UCHL1(gray
and of Actin and further normalized as the ratios of the UCHL1 knockdown group
) and quantitative data (bottom) show unchanged CHT mRNA expression between
ated as relative densities (ratio) of the bands of CHT against the band of beta actin.
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end quantitative data (right bar graphs) show the changes in cytosolic CHT, memb
argeting UCHL1 (gray bars). All groups n=11.
anel) proteins in the CHT antibody pull-down sample but not in
he control IgGpull-downsample, suggesting aphysical interaction
etween UCHL1 and CHT. In attempt for reciprocal IP pulling down
f UCHL1, we have not yet found a commercially available UCHL1
ntibody suitable for IP at this time.
.2. The effect of UCHL1 knockdown on CHT ubiquitination
The treatment with siRNA targeting UCHL1 signiﬁcantly
ecreased UCHL1 protein level versus the treatment with
ontrol siRNA (Fig. 2A). Consequently, the high molecular poly-
biquitinated CHT was signiﬁcantly increased, whereas the native
HT protein (∼55kDa band) level was signiﬁcantly decreased.
hese results suggest UCHL1 may function as a DUB to negatively
egulate CHT ubiquitination and degradation.
We also measured CHT mRNA expression using semi-
uantitative RT-PCR. The result showed no signiﬁcant difference
etween the groups treated with control siRNA or UCHL1 siRNA
Fig. 2B), suggesting the reduction of CHT protein level is due to a
ost-translational mechanism.
.3. The effect of UCHL1 knockdown on cytosolic and membrane
HT
As assessed by biotinylation and immunoblotting in Fig. 3,
CHL1 protein was solely present in the cytosolic sample and
as signiﬁcantly reduced in the cells treated with siRNA target-
ng UCHL1. The native CHT (∼55kDa band) was present in both
ytosolic and membrane fractions. The cytosolic CHT protein was
igniﬁcantly reduced in the UCHL1 knockdown sample, which is
onsistent with the previous result. The level of plasma membrane
HT in UCHL1 siRNA treated cells was not statistically different
ersus the control siRNA group.
. Discussion
UCHL1 was discovered as a prominent, neuronal DUB for over
wo decades [29] but its biological substrates remain to be deﬁned
8]. Using an in vitro cholinergic cell model, this report provides
ovel evidence that UCHL1 may physically interact with CHT and
unctionally affect CHT ubiquitination and native CHT protein level.
hese data suggest that UCHL1 may function as a DUB targeting
HT in cholinergic neurons. Given the importance of CHT in Ach
e-synthesis, these data suggest that UCHL1may play an important
ole in regulating cholinergic function in both central and periph-
ral nervous systems.CHT, and UCHL1from SN56 cells treated with control siRNA (black bars) or siRNA
CHT is functionally localized in the pre-synaptic membrane for
the re-uptake of choline, which is the rate-limiting step for Ach re-
synthesis [26,27]. Todate, the roleofubiquitinandubiquitination in
the regulation of cholinergic function and CHT is largely unknown.
A few recent studies suggest that CHT may be ubiquitinated [31]
andubiquitinationmaybe involved inoxidative stress inducedpro-
tein degradation of CHT [7]. Using TUBE pull-down assay, our study
provides novel evidence that CHT undergoes poly-ubiquitination.
Furthermore, our results reveal that reduction of UCHL1 level by
siRNA knockdown increases poly-ubiquitinated CHT and decreases
thenativeCHT level. These results suggest thatUCHL1 functionsasa
DUB to negatively regulate CHT ubiquitination. Thus, the reduction
of UCHL1 leads to an increase in CHT poly-ubiquitination and con-
sequently a decrease in native CHTproteins.Whether the increased
poly-ubiquitination results in an increase in CHT protein degrada-
tion via the proteasome or lysosome systems remains to be further
elucidated.
Recent studies reveal that CHT undergoes constant, dynamic
trafﬁcking between theplasmamembrane and cytosol [10,26]. Pro-
tein ubiquitination is critical in regulating protein trafﬁcking [18].
To test the potential role of UCHL1 and ubiquitination in CHT traf-
ﬁcking, we assessed the CHT level in the plasmamembrane using a
biotinylationassay. The results showed thatUCHL1 is solelypresent
in the cytosol in this cell line. Additionally, the reduction of UCHL1
by siRNA knockdown signiﬁcantly decreased cytosolic CHT protein
but did not signiﬁcantly alter the CHT level in the plasma mem-
brane. It shouldbenoted that this studyonlyexamined theeffectsof
UCHL1 on membrane CHT at resting conditions. Whether and how
UCHL1 affects CHT protein trafﬁcking during excitation, choline
accumulation, and other challenging conditions needs to be further
examined.
Acetylcholine is amajor neurotransmitter in the central nervous
system, the autonomic nervous system, and the neuromuscular
junction. The role of UCHL1 in regulating cholinergic function may
have potentially important clinical implications. For example, pre-
vious studies have suggested that altered UCHL1 activity may be
involved inAlzheimer’s disease [4,28]. In the brains of patientswith
Alzheimer’s disease, UCHL1 was down-regulated and the UCHL1
protein levelswere inversely proportional to the number of neuron
tangles [6,11]. It is well-known that reduced cholinergic func-
tion is one of the hallmarks in Alzheimer’s disease [19]. Whether
the reduced UCHL1 may contribute to the impaired cholinergic
function in Alzheimer’s disease is certainly worth further inves-
tigation.
The results reported in this study are novel, interesting, and
important for further investigation. Importantly, the functional
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urther investigated in appropriate physiological and pathophys-
ological models. SN56 is a widely used cholinergic cell line that
xpresses major cholinergic proteins and is a suitable in vitro
odel for studying the regulation and modiﬁcations of choliner-
ic proteins such as CHT. It would be important to conﬁrm these
ndings in other cell lines, primary neurons, and in vivo models
uring normal and disease conditions. Additionally, as mentioned
arlier, the effect of UCHL1 on CHT degradation and trafﬁcking
uring excitation, stimulation, and pathological conditions needs
o be further examined. The physical interaction of UCHL1 and
HT needs to be further conﬁrmed by the reciprocal IP of both
HT and UCHL1. As the antibodies suitable for UCHL1 IP are not
ommercially available, establishing the co-expression of tagged
CHL1 and CHT would be essential for carrying out such experi-
ents.
Nevertheless, thedata fromthis study reveals anovel andpoten-
ially important role of UCHL1 in regulating CHT level. It opens
new direction for further investigations into the mechanisms
egulating cholinergic function and dysfunction in the central and
eripheral nervous systems.
. Conclusion
Thedata from this study suggest thatUCHL1physically interacts
ith CHT and functions as a deubiquitinating enzyme to regulate
HT ubiquitination and protein level in cholinergic cells.
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